VerifiedPharmaceutical Manufacturing· Founded 1999

Xenoport, Inc

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

7-day free trial · no credit card

113(51 to 200)1999xenoport.com LinkedIn

Verified contacts

105

available on Kipplo

LinkedIn employees

113

51 to 200 range

Open roles

—

no listings

Distinct roles

78

indexed titles

Tech stack

1

tools in use

Monthly traffic

—

organic / mo

Sign up free to see all 105 verified contacts at Xenoport, Inc

Free for 7 days · 50 credits · no card · only pay for verified records.

Decision-makers and verified team members

105 contacts with verified email or phone · masked until revealed.

Sign up free →

Showing 9 of 105 verified contacts

Top roles at Xenoport, Inc

78 distinct titles indexed · top 10 shown.

5director
3consultant
3regional sales director
3research associate
3sr scientist
2neurohealth specialist
2senior scientist
2staff scientist
1-' &
1accountant
+68more titles

Sign up to unlock all 105 contacts at Xenoport, Inc

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up to reveal 105 verified contacts at Xenoport, Inc

7-day trial · no credit card · cancel anytime · only pay for verified records.

Sign up free See pricing

Trusted by sales, marketing, and GTM engineering teams.

Xenoport, Inc | Kipplo Discover